Seeking Alpha

Seeking Alpha Portfolio App for iPad

Steven Breazzano

Steven Breazzano picture

Steven Breazzano

Profile

Send Message

View as an RSS Feed

View Steven Breazzano's Articles BY TICKER:

Obesity Sector Update And Compelling Short Opportunity
on Mon, Nov 12, 2012 • OREX, VVUS, ARNA • 113 Comments
4 Biotechs Targeting Fibrosis
on Wed, Oct 17, 2012 • GALT, ITMN, LJPC • 4 Comments
Raptor Pharmaceuticals: Stock Below Fair Value With Recent Pullback
on Tue, Jul 10, 2012 • RPTP • 4 Comments
NPS Pharmaceuticals: Misunderstood Assets And Compelling Value Play
on Wed, Jun 27, 2012 • NPSP • 4 Comments
Seattle Genetics Shares Continue To Impress - And It's Not Too Late To Buy
on Mon, Jun 11, 2012 • CLDX, SGEN • 4 Comments
Not All Biotechnology ETFs Created Equal
on Fri, Jun 8, 2012 • XBI, IBB, PJP • 6 Comments
Protalix BioTherapeutics Finally Receives FDA Approval To Market Elelyso For Enzyme Replacement Therapy In Gaucher's Disease
on Tue, May 1, 2012 • PFE, SNY, PLX • 3 Comments
Coronado Biosciences: What Do The Recent Trial Changes Mean For Investors?
on Tue, May 1, 2012 • ABT, JNJ, CNDO • 4 Comments
LPath's Form / Fill Delay Disappoints Investors: Long-Term Buying Opportunity?
on Thu, Feb 2, 2012 • PFE, LPTN • 10 Comments
Coronado Biosciences: Phase II Trials Provide Multiple Shots On Goal
on Tue, Jan 31, 2012 • CNDO • 5 Comments
Biotech Class Of 2010: IPOs Revisited
on Wed, Jan 4, 2012 • IRWD, ANTH, AVEO • 3 Comments
Seattle Genetics: Innovative Biotech, Speculative Stock
on Sun, Jan 1, 2012 • IMGN, SGEN • 7 Comments
Protalix BioTherapeutics: FDA Delay Provides Attractive Entry Point
on Wed, Dec 7, 2011 • PLX • 10 Comments
Prolor Biotech: De-Risked And Ready To Begin Phase 3 Trials
on Wed, Nov 23, 2011 • MAXY, RHHBY.OB, BIIB • 8 Comments
DUSA Pharmaceuticals Shares Tumble After Earnings: Low Growth Ahead?
on Fri, Nov 11, 2011 • DUSA • 11 Comments
LPath Investors Have iSONEP Trial Results In Sight
on Wed, Nov 2, 2011 • BMY, PFE, RHHBY.OB • 3 Comments
Raptor Pharmaceuticals Provides Update On Lead Candidate: RP103
on Mon, Oct 31, 2011 • RPTP • Comment!
Savient Pharmaceuticals: Value Play Or Value Trap?
on Thu, Sep 22, 2011 • SVNT • 22 Comments
Raptor Pharmaceuticals Announces Positive Phase 3 Trial Results: Shares Tumble
on Fri, Jul 29, 2011 • RPTP • 3 Comments
iBio: Recent Lull Offers Opportunity to the Patient Investor
on Wed, Jul 27, 2011 • IBIO • 9 Comments
Biotech Valuation Part 2: Market Size and rNPV Applied to Prolor Biotech
on Thu, Jul 21, 2011 • VVUS, PFE, LLY • 12 Comments
Biotech Valuation Part 1: Science, Patents, and Management
on Thu, Jul 21, 2011 • SVNT, DCTH • 14 Comments
Prolor Biotech: Interim Phase 2 Data Promising
on Mon, Jun 20, 2011 • BIIB, PBTH • 2 Comments
DUSA Pharmaceuticals: Recent Pullback Provides Attractive Entry Point
on Tue, May 10, 2011 • DUSA • 23 Comments
Ariad Pharmaceuticals and PACE: First Quarter Earnings Highlights
on Thu, May 5, 2011 • ARIA • 3 Comments
Alternative Vaccine Manufacturers: Novavax and Ibio
on Thu, Apr 28, 2011 • NVAX, IBIO • 11 Comments
Raptor Pharmaceuticals: Pipeline Worth a Closer Look
on Wed, Mar 30, 2011 • RPTP, LLY, RHHBY.OB • 4 Comments
Depomed's Recent Events Boost Balance Sheet
on Mon, Mar 21, 2011 • ABT, DEPO • 2 Comments
DUSA Pharmaceuticals: Small-Cap Biotech With a Healthy Cash Flow
on Mon, Mar 14, 2011 • DUSA • 2 Comments
The Patent Cliff: What Big Pharma Investors Need to Know
on Fri, Mar 11, 2011 • SNY, MRK, BMY • 10 Comments
Why Phase 3 Trials Fail: What Investors Need to Know
on Mon, Mar 7, 2011 • MDVN, RPTP, OMER • 17 Comments
Earnings Analysis: Ariad Pharmaceuticals
on Mon, Feb 28, 2011 • ARIA • Comment!